225Ac-PSMA-62 News - LARVOL Sigma

||||||||||  225Ac-PSMA-62 / Eli Lilly
Enrollment change, Metastases:  ACCEL: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Sep 19, 2024
P1, N=142, Recruiting,  Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Presented at EANM Oct 2022, Barcelona, Spain. N=48 --> 142

|||||||||| 225Ac-PSMA-62 / Eli Lilly
First in human evaluation of PSMA-62: Intraindividual comparison of [Ga-68]-PSMA-62 and [Ga-68]-PMSA-11 PET/CT in patients with mCRPC (714B (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_2253;
In addition, [Ga-68]-PSMA-62 has significantly lower salivary gland uptake relative to [Ga-68]-PSMA-11. These preliminary clinical data with [Ga-68]-PSMA-62 are encouraging and suggest that therapy with [Ac-225]-PSMA-62 may lead to reduced incidence and severity of xerostomia relative to currently available PSMA directed radioligands.

||||||||||  225Ac-PSMA-62 / Eli Lilly
Enrollment open, Metastases:  ACCEL: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Apr 23, 2024
P1, N=48, Recruiting,  Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
These preliminary clinical data with [Ga-68]-PSMA-62 are encouraging and suggest that therapy with [Ac-225]-PSMA-62 may lead to reduced incidence and severity of xerostomia relative to currently available PSMA directed radioligands. Not yet recruiting --> Recruiting

||||||||||  225Ac-PSMA-62 / Eli Lilly
New P1 trial, Metastases:  ACCEL: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Jan 28, 2024
P1, N=48, Not yet recruiting,  Sponsor: POINT Biopharma



	Diseases Companies Products Productz Mechanisms of Action Sites